Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Altomare, H. You, G. Xiao, M. Ramos-Nino, Kristine Skele, A. Rienzo, S. Jhanwar, B. Mossman, A. Kane, J. Testa (2005)
Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growthOncogene, 24
B. Robinson, R. Lake (2005)
Advances in malignant mesothelioma.The New England journal of medicine, 353 15
Pass (2004)
Malignant pleural mesotheliomaCurr. Probl. Cancer, 28
R. Jagadeeswaran, P. Ma, T. Seiwert, Sujatha Jagadeeswaran, Osvaldo Zumba, V. Nallasura, Salman Ahmed, R. Filiberti, M. Paganuzzi, R. Puntoni, R. Kratzke, G. Gordon, D. Sugarbaker, R. Bueno, Varalakshmi Janamanchi, V. Bindokas, H. Kindler, R. Salgia (2006)
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.Cancer research, 66 1
T. Mitsudomi, Y. Yatabe (2007)
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancerCancer Science, 98
R. Govindan, R. Kratzke, J. Herndon, G. Niehans, R. Vollmer, D. Watson, Mark Green, H. Kindler (2005)
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group BClinical Cancer Research, 11
G. Kapoor, D. O’Rourke (2003)
Receptor Tyrosine Kinase Signaling In Gliomagenesis: Pathobiology And Therapeutic ApproachesCancer Biology & Therapy, 2
J. Meerbeeck, R. Gaafar, C. Manegold, R. Klaveren, E. Marck, M. Vincent, C. Legrand, A. Bottomley, C. Debruyne, G. Giaccone (2005)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 28
Yutaro Suzuki, H. Murakami, K. Kawaguchi, T. Tanigushi, M. Fujii, Keiko Shinjo, Y. Kondo, H. Osada, K. Shimokata, Y. Horio, Y. Hasegawa, T. Hida, Y. Sekido (2009)
Activation of the PI3K-AKT pathway in human malignant mesothelioma cells.Molecular medicine reports, 2 2
A. Mathy, P. Baas, O. Dalesio, N. Zandwijk (2005)
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.Lung cancer, 50 1
M. Ramael, C. Buysse, J. Bossche, K. Segers, E. Marck (1992)
Immunoreactivity for the β chain of the platelet‐derived growth factor receptor in malignant mesothelioma and non‐neoplastic mesotheliumThe Journal of Pathology, 167
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
A. Langerak, P. LAAT, C. Beurden, M. Delahaye, T. Kwast, H. Hoogsteden, R. Benner, M. Versnel (1996)
EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVOThe Journal of Pathology, 178
Pao (2004)
EGF receptor gene mutations are common in lung cancers from ?never smokers? and are associated with sensitivity of tumors to gefitinib and erlotinibProc. Natl Acad. Sci. USA, 101
M. Beau-Faller, A. Ruppert, Anna Voegeli, A. Neuville, Nicolas Meyer, E. Guérin, M. Legrain, B. Mennecier, J. Wihlm, G. Massard, E. Quoix, P. Oudet, M. Gaub (2008)
MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve CohortJournal of Thoracic Oncology, 3
A. Destro, G. Ceresoli, M. Falleni, P. Zucali, E. Morenghi, P. Bianchi, C. Pellegrini, N. Cordani, V. Vaira, M. Alloisio, A. Rizzi, S. Bosari, M. Roncalli (2006)
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.Lung cancer, 51 2
P. Harvey, A. Warn, P. Newman, L. Perry, R. Ball, R. Warn (1996)
IMMUNOREACTIVITY FOR HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND ITS RECEPTOR, met, IN HUMAN LUNG CARCINOMAS AND MALIGNANT MESOTHELIOMASThe Journal of Pathology, 180
C. Porta, L. Mutti, G. Tassi (2006)
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesotheliomaCancer Chemotherapy and Pharmacology, 59
N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffié, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, P. Paoletti (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
M. Moasser (2007)
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 26
J. Peto, J. Peto, A. Decarli, C. Vecchia, F. Levi, E. Negri (1999)
The European mesothelioma epidemicBritish Journal of Cancer, 79
J. Stommel, Alec Kimmelman, H. Ying, R. Nabioullin, Aditya Ponugoti, R. Wiedemeyer, A. Stegh, J. Bradner, K. Ligon, C. Brennan, L. Chin, R. DePinho (2007)
Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted TherapiesScience, 318
Susumu Kobayashi, T. Boggon, Tajhal Dayaram, P. Jänne, O. Kocher, M. Meyerson, B. Johnson, M. Eck, D. Tenen, B. Halmos (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 352 8
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
T. Murayama, Ken Takahashi, Y. Natori, N. Kurumatani (2006)
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.American journal of industrial medicine, 49 1
M. Renzo, M. Olivero, A. Giacomini, H. Porte, E. Chastre, L. Mirossay, B. Nordlinger, S. Bretti, S. Bottardi, S. Giordano (1995)
Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 1 2
N. Usami, T. Fukui, M. Kondo, T. Taniguchi, T. Yokoyama, S. Mori, K. Yokoi, Y. Horio, K. Shimokata, Y. Sekido, T. Hida (2006)
Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patientsCancer Science, 97
Harvey Pass, Nicholas Vogelzang, Stephen Hahn, Michele Carbone (2004)
Malignant pleural mesothelioma.Current problems in surgery, 30 10
J. Engelman, K. Zejnullahu, T. Mitsudomi, Youngchul Song, Courtney Hyland, Joon-Oh Park, N. Lindeman, Christopher-Michael Gale, Xiaojun Zhao, J. Christensen, T. Kosaka, A. Holmes, A. Rogers, F. Cappuzzo, T. Mok, Charles Lee, B. Johnson, L. Cantley, P. Jänne (2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 316
L. Garland, C. Rankin, D. Gandara, S. Rivkin, K. Scott, R. Nagle, Andres Klein-Szanto, J. Testa, D. Altomare, E. Borden (2007)
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 17
T. Mukohara, G. Civiello, I. Davis, M. Taffaro, J. Christensen, D. Fisher, B. Johnson, P. Jänne (2005)
Inhibition of the Met Receptor in MesotheliomaClinical Cancer Research, 11
M. Versnel, L. Claesson-Welsh, A. Hammacher, M. Bouts, van Th, A. Eriksson, R. Willemsen, Weima Sm, Hoogsteden Hc, A. Hagemeijer (1991)
Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors.Oncogene, 6 11
C. Birchmeier, W. Birchmeier, E. Gherardi, G. Woude (2003)
Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 4
E. Tolnay, C. Kuhnen, T. Wiethege, J. König, B. Voss, K. Müller (1998)
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesotheliomaJournal of Cancer Research and Clinical Oncology, 124
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proceedings of the National Academy of Sciences of the United States of America, 101 36
T. Taniguchi, S. Karnan, T. Fukui, T. Yokoyama, H. Tagawa, K. Yokoi, Y. Ueda, T. Mitsudomi, Y. Horio, T. Hida, Y. Yatabe, M. Seto, Y. Sekido (2007)
Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32Cancer Science, 98
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm associated with asbestos exposure. Although expression and activation of receptor tyrosine kinases (RTKs), including MET, have been reported in most MPM, specific RTK inhibitors showed less than the expected response in MPM cells. To determine whether the lack of response of MET inhibitors was due to cooperation with other RTKs, we determined activation status of MET and other RTKs, including epidermal growth factor receptor (EGFR) family of 20 MPM cell lines, and tested whether dual RTK inhibition is an effective therapeutic strategy. We detected MET upregulation and phosphorylation (thus indicating activation) in 14 (70%) and 13 (65%) cell lines, but treatment with MET-specific inhibitors showed weak or modest effect of suppression in most of the cell lines. Phospho-RTK array analysis revealed that MET was simultaneously activated with other RTKs, including EGFR, ErbB2, ErbB3 and platelet-derived growth factor receptor-. Combination of MET and EGFR inhibitors triggered stronger inhibition on cell proliferation and invasion of MPM cells than that of each in vitro. These results indicated that coactivation of RTKs was essential in mesothelioma cell proliferation and/or survival, thus suggesting that simultaneous inhibition of RTKs may be a more effective strategy for the development of molecular target therapy for MPM.
Carcinogenesis – Oxford University Press
Published: Apr 20, 2009
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.